Last reviewed · How we verify
SK Antithrombin III — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
SK Antithrombin III (SK Antithrombin III) — SK Chemicals Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SK Antithrombin III TARGET | SK Antithrombin III | SK Chemicals Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SK Antithrombin III CI watch — RSS
- SK Antithrombin III CI watch — Atom
- SK Antithrombin III CI watch — JSON
- SK Antithrombin III alone — RSS
Cite this brief
Drug Landscape (2026). SK Antithrombin III — Competitive Intelligence Brief. https://druglandscape.com/ci/sk-antithrombin-iii. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing